tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Cardiol Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Cardiol Therapeutics (CRDL) with a Buy rating and $9 price target Cardiol is a clinical-stage company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, the analyst tells investors in a research note. The firm says Cardiol is currently advancing CardiolRx in two lead programs that target recurrent pericarditis and acute myocarditis. It believes investors could soon come to appreciate the value to be unlocked within the company.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1